Therapeutic Indication

PIVOT 006 Lowers Bladder Tumor Recurrence

CG Oncology reported a Phase 3 recurrence-free-survival hazard ratio of 0.32 for adjuvant intravesical cretostimogene versus surveillance after complete tumor resection in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer. It remains investigational; full results…

JW Discloses CARTEYVA Reimbursement Price

JW Therapeutics disclosed a RMB288,600 National Reimbursement Drug List price for relmacabtagene autoleucel, effective 1 January 2027, covering three lymphoma indications. This product-level price is new information beyond China’s 14 November list announcement. Access…